Katharine Berghuis Stevenson is Director at Valeant Pharmaceuticals International, Inc. (VRX). They have made 6 open-market trades across 2 companies since 2006, most recently 2015-05-22.
CIK 0001232227
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
4 open-market purchases totalling $415K since 2010, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| VRX | BUY | 2014-12-03 | 2014-12-03 | $145.73 | $219K | -12.8% | +0.4% | +0.4% |
| VRX | BUY | 2011-08-08 | 2011-08-09 | $39.73 | $40K | -12.8% | +0.4% | +0.4% |
| VRX | BUY | 2011-03-14 | 2011-03-16 | $40.59 | $81K | -12.8% | +0.4% | +0.4% |
| VRX | BUY | 2010-11-29 | 2010-12-01 | $25.33 | $76K | -12.8% | +0.4% | +0.4% |
| NT | SELL | 2007-06-20 | 2007-06-21 | $25.18 | $16K | N/A | N/A | N/A |
| NT | SELL | 2006-09-13 | 2006-09-15 | $2.33 | $14K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.